Anxiety symptoms in patients with heart failure - correlation with natriuretic peptides and their modulation during treatment

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012906

Enrollment

Registered

2017-09-08

Start date

2017-08-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I50

Interventions

Group 1: Entresto (Sacubitril and Valsartan), 49mg/51mg p. o. (tablet), for 14 days (study-independent standard therapy) Group 2: Non-Sacubitril (other study-independent standard therapy)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Heart failure NYHA II-IV

Exclusion criteria

Exclusion criteria: Pregnancy

Design outcomes

Primary

Measure	Time frame
Anxiety (according to Hospital Anxiety and Depression Scale) - questionnaire (self report) - Performed on days 0, 7, 14	—

Secondary

Measure	Time frame
Atrial natriuretic peptide in plasma - radioimmunoassay after extraction - performed on days 0, 7, 14	—

Countries

Germany

Contacts

Public ContactMichael Kellner

Klinikum Herford

michael.kellner@klinikum-herford.de05221 9428300

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026